Literature DB >> 18670304

Waiting times in early-stage non-small cell lung cancer (NSCLC).

Nathalie Saint-Jacques1, Daniel Rayson, Turki Al-Fayea, Kiran Virik, Wojciech Morzycki, Tallal Younis.   

Abstract

INTRODUCTION: Wait times in cancer care continue to be an important clinical, social, and political issue. This study examines wait times along the care path from suspicious imaging study (Detection) to adjuvant chemotherapy initiation (Chemotherapy) for patients with early-stage non-small cell lung cancer (NSCLC) who undergo surgical resection.
METHODS: A retrospective chart review of patients diagnosed in 2005 with NSCLC who underwent curative-intent surgery in Nova Scotia, Canada was conducted to abstract dates of care events (Detection, Surgery Consultation, Surgery, Medical Oncology [MO] Referral, MO Consultation and Chemotherapy) and patient characteristics. Multifactorial regression methods were used to identify statistically-significant cofactors associated with wait times at various resolutions of care intervals (low, intermediate, high).
RESULTS: A median wait time of 141 days elapsed between Detection-Chemotherapy; and a median 107 and 52 days elapsed between Detection-Surgery and Surgery-Chemotherapy, respectively. A number of demographic, clinical, epidemiological, and system resource dependant factors influenced wait times at different resolutions, and were best detailed utilizing high resolution analysis. Wait time between MO referral-MO Consultation was inversely related to that experienced in the preceding interval of Surgery-MO Referral.
CONCLUSIONS: This study provides a first detailed examination of wait times experienced by NSCLC patients undergoing curative-intent surgery according to care interval definitions; demonstrates the value of high care interval resolution analysis to detect bottlenecks in access to care; and reports on the interdependence of elapsed times between care events along the care path for cancer patients.

Entities:  

Mesh:

Year:  2008        PMID: 18670304     DOI: 10.1097/JTO.0b013e318180210c

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

1.  Chemotherapy uptake and wait times in early-stage non-small-cell lung cancer.

Authors:  S Gray; J Bu; N Saint-Jacques; D Rayson; T Younis
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

2.  Survival after community diagnosis of early-stage non-small cell lung cancer.

Authors:  Norma F Kanarek; Craig M Hooker; Luckson Mathieu; Hua-Ling Tsai; Charles M Rudin; James G Herman; Malcolm V Brock
Journal:  Am J Med       Date:  2014-01-28       Impact factor: 4.965

3.  Improving wait time for chemotherapy in an outpatient clinic at a comprehensive cancer center.

Authors:  Michael A Kallen; James A Terrell; Paula Lewis-Patterson; Jessica P Hwang
Journal:  J Oncol Pract       Date:  2012-01       Impact factor: 3.840

4.  Using a Dedicated Interventional Pulmonology Practice Decreases Wait Time Before Treatment Initiation for New Lung Cancer Diagnoses.

Authors:  Bryan S Benn; Mihir Parikh; Pei H Tsau; Eric Seeley; Ganesh Krishna
Journal:  Lung       Date:  2019-02-19       Impact factor: 2.584

5.  High resolution analysis of wait times and factors affecting surgical expediency.

Authors:  Eric Cole; Wilma Hopman; Jun Kawakami
Journal:  Can Urol Assoc J       Date:  2011-02       Impact factor: 1.862

6.  Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis.

Authors:  Daniel Rayson; Robin Urquhart; Martha Cox; Eva Grunfeld; Geoff Porter
Journal:  J Oncol Pract       Date:  2012-07       Impact factor: 3.840

7.  Managing patient pathways to achieve lung cancer waiting time targets: mixed methods study.

Authors:  Hugh Ip; Tarik Amer; Michael Dangoor; Affan Zamir; Darryl Gibbings-Isaac; Ranjeev Kochhar; Timothy Heymann
Journal:  JRSM Short Rep       Date:  2012-10-15

8.  Transfer between hospitals as a predictor of delay in diagnosis and treatment of patients with Non-Small Cell Lung Cancer - a register based cohort-study.

Authors:  Maria Iachina; Erik Jakobsen; Anne Kudsk Fallesen; Anders Green
Journal:  BMC Health Serv Res       Date:  2017-04-12       Impact factor: 2.655

Review 9.  Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature.

Authors:  Anne-Laure Desage; Wafa Bouleftour; Olivier Tiffet; Pierre Fournel; Claire Tissot
Journal:  Transl Lung Cancer Res       Date:  2021-12

Review 10.  Socio-economic inequalities in stage at diagnosis, and in time intervals on the lung cancer pathway from first symptom to treatment: systematic review and meta-analysis.

Authors:  Lynne F Forrest; Sarah Sowden; Greg Rubin; Martin White; Jean Adams
Journal:  Thorax       Date:  2016-09-28       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.